NCT03219671

Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

A Phase 2 Study of Nivolumab Plus Ipilimumab in Previously Treated Classical Kaposi Sarcoma (CKS)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Alona Zer · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)

Detailed description

A prospective, single arm, interventional study. All patients will receive IV nivolumab 3mg/kg every two weeks and ipilimumab 1mg/kg every 6 weeks. Patients will be treated until disease progression or intolerable toxicity for a maximal period of two years, with an option to re-initiate therapy upon progression in patients with prior documented response to investigational therapy (unless treatment was held for progression of disease).

Conditions

• Classic Kaposi Sarcoma

Interventions

Type	Name	Description
DRUG	Nivolumab	nivolumab 240mg every 2 weeks
DRUG	Ipilimumab	ipilimumab 1 mg/kg every 6 weeks

Timeline

• Start date: 2018-04-01
• Primary completion: 2020-09-01
• Completion: 2022-09-01
• First posted: 2017-07-17
• Last updated: 2018-12-26

Locations

1 site across 1 country: Israel